Alembic Pharmaceuticals Reschedules Q2 FY27 Earnings Call to 4th Nov'26
Alembic Pharmaceuticals Ltd 路 Intimation 路 04 Nov 2026, 5:00 pm
Alembic Pharmaceuticals Reschedules Q2 FY27 Earnings Call to 4th Nov'26 Alembic Pharmaceuticals Limited has rescheduled its post-results conference call for analysts and institutional investors to discuss its Q2 FY27 unaudited financial results. The call is now set for 4th Nov'26 at 5:00 PM IST with the senior management team. Participants can join via pre-registration through Diamond Pass or via universal dial-in numbers (+91 22 6280 1411 / +91 22 7115 8312) alongside international toll-free options for the USA, UK, Singapore, and Hong Kong.
Original exchange filing (PDF)
More announcements from Alembic Pharmaceuticals Ltd
- Alembic Pharmaceuticals Limited receives USFDA Final Approval for Binimetinib Tablets, 15 mg and 45 mg. 路 15 Nov 2026
- Please find attached herewith the Transcript of Post Results Conference Call held on 4th November, 2026. 路 10 Nov 2026
- Alembic Pharmaceuticals Limited receives USFDA Final Approval for Olopatadine Hydrochloride Ophthalmic Solution USP, 0.7% (OTC). 路 05 Nov 2026
- Please find attached Audio Recording of Investor Call. 路 05 Nov 2026
- Please find attached intimation under Regulation 30(5) of SEBI (LODR) Regulations, 2015. 路 04 Nov 2026
- Please find attached Press Release 路 04 Nov 2026
- Please find attached Investor Presentation for the Quarter and Half Year Ended September 30, 2026. 路 04 Nov 2026
- Please find attached Press Release for the Quarter and Half Year Ended September 30, 2026. 路 04 Nov 2026
